Qelbree

Supernus Pharmaceuticals and Indivior Pharmaceuticals have completed their merger, establishing a diversified central nervous system drug company with approximately $2.2 billion in historical pro forma annual revenue. The transaction combines five core growth medicines and targets $125 million in annual cost savings, but a $1 billion special dividend and new debt obligations place financial discipline alongside commercial expansion.